- NfL: neurodegeneration biomarker in multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's disease and other indications.
- Tau: Alzheimer's disease, frontotemporal dementia.
- Aβ42, Aβ40: Alzheimer's disease, frontotemporal dementia.
- UCHL1, NfL, Tau GFAP: traumatic brain injury, stroke.
Quanterix® SIMOA™ Assays
Precision offers ultra-sensitive biomarker detection using Quanterix SIMOA
Advancing biomarker-driven research through femtomolar detection and quantification of low abundance or challenging biomarkers
Example uses of Quanterix SIMOA
- Biomarker discovery: quantify previously unmeasurable proteins and nucleic acids
- Uncover Dx and CDx opportunities
- Protein counting in single cancer cells
- Measurement of neurology biomarkers in matrices other than CSFm
- PK/ADA assays (gene therapy)
Sample types analyzed:
- Plasma
- Serum
- CSF
- Urine
- Cell extracts
Selection of key biomarkers targets and uses :
Neurology
Gene therapy
- AAV antibodies: TAb assays in gene therapy.
- Transgene products
Oncology/Immunology
- Cytokine panels
- Inflammatory proteins
Neurology applications of SIMOA technology
Historically, several important neurology biomarkers, including neurofilament light chain (NfL) and phosphorylated neurofilament heavy chain (P-NfH) could only be reliably measured in cerebrospinal fluid (CSF). Plasma/serum (or blood) concentrations of these biomarkers are too low for detection using standard ELISA methods.
Utilizing the 1000-fold higher sensitivity of the SIMOA platform, Precision can reliably measure these biomarkers from blood draws, offering significant benefits in neurology studies:
- Lower patient burden – Sampling CSF can be challenging and is associated with higher patient discomfort and an increased risk of complications. In contrast, blood draws are easier on patients and have a lower risk of complications.
- Improved longitudinal data – Because blood draws are more accessible, samples may be collected more frequently and in larger volumes than when sampling CSF. This helps build a richer and more informative biomarker data set over time for each patient and across patients.
Gold standard biomarkers in neurology therapeutic development
Discover biomarker approaches specific to neurology therapeutic development, including how SIMOA assays can be used for measurement of CNS-specific biomarkers in blood.
Developing a comprehensive biomarker strategy for neurology therapeutic development
Download WhitepaperRelated services
-
Explore
Large Molecule PK
Development, validation, and implementation using ELISAs and MSD assays for biologics, flow cytometry and ddPCR for cell-based therapies, and Quanterix SIMOA® for ultrasensitive analyte detection -
Explore
MesoScale Discovery (MSD)
Measuring a range of analytes in complex sample matrices consistently and at high sensitivity, with applications including ADA, NAb, TAb, and PK assays -
Explore
ELISA
Services using the gold standard for quantitative antibody-based bioanalysis, with specialization in immunogenicity assay development